Evotec to Report Third Quarter 2009 Results on 12 November 2009

HAMBURG, Germany, Nov. 6, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (Nasdaq:EVTC) will report its financial results for the third quarter of 2009 on Thursday, 12 November 2009.

The Company is going to hold a conference call to discuss the results and to give an update on its business strategy:

   Conference call details:
   Date:        Thursday, 12 November 2009
   Time:        09.30 a.m. CST
                08.30 a.m. GMT
                03.30 a.m. US time (East Coast)

   From Europe: +49.(0)69.2222 9550 (Germany)
                +44.(0)20.7784 1036 (UK)
   From the US: +1.718.354 1152
   Access Code: 9023741

A simultaneous slide presentation for participants dialing in via phone is available at www.equitystory.com, password: evotec121109.

Webcast details

To join the audio webcast and to access the presentation slides you will find a link on our home page www.evotec.com shortly before the event.

A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialing +49.(0)69.2222 2236 (Germany) or +44.(0)20.7111 1244 (UK) and in the US by +1.347.366 9565. The access code is 9023741#. The on-demand version of the webcast will be available on our website: www.evotec.com - Investors - Finance - Financial Reports 2008 - 2009.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has built substantial drug discovery expertise and an industrialized platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, and inflammation. Leveraging these skills and expertise, the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including for example a strategic alliance with Roche for the EVT 100 compound family, subtype selective NMDA receptor antagonists for use in treatment-resistant depression. For additional information please go to www.evotec.com.

CONTACT:  Evotec AG
          Dr Werner Lanthaler, Chief Executive Officer
          +49.(0)40.56081-242
          werner.lanthaler@evotec.com